<DOC>
	<DOC>NCT00469092</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, Oceania and South America. This trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and glimepiride in insulin naive subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 2 diabetes Treatment with OADs (Oral AntiDiabetic Drugs) for more than 6 months Ongoing stable treatment with metformin for at least 2 months Ongoing stable treatment with minimum half maximal dose of any insulin secretagogue for at least 2 months Insulin naive HbA1c (glycosylated haemoglobin A1c) between 7.0% and 11.0% (inclusive of both values) Metformin contraindication according to local practice TZD (thiazolidinedione) treatment for the last 5 months before trial start Systemic treatment with any corticosteroid 3 months before trial start Any disease or condition which according to the Investigator would interfere with the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>